Zanwar S, Nandakumar B, Kumar S. Immune-based therapies in the management of multiple myeloma. Blood Cancer J. 2020;10:84.

Article  PubMed  PubMed Central  Google Scholar 

Rasche L, Wäsch R, Munder M, Goldschmidt H, Raab MS. Novel immunotherapies in multiple myeloma—chances and challenges. Haematologica. 2021;106:2555–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood. 2023;141:756–65.

Article  PubMed  Google Scholar 

Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. Br J Haematol. 2022;196:488–506.

Article  CAS  PubMed  Google Scholar 

Schürch CM, Rasche L, Frauenfeld L, Weinhold N, Fend F. A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. Virchows Arch Int J Pathol. 2020;476:337–51.

Article  Google Scholar 

Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464–77.

Article  CAS  PubMed  Google Scholar 

Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol. 2014;165:441–54.

Article  PubMed  Google Scholar 

Hervé AL, Florence M, Philippe M, Michel A, Thierry F, Kenneth A, et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol J Am Soc Clin Oncol. 2011;29:1893–7.

Article  Google Scholar 

Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol J Am Soc Clin Oncol. 2024;42:1229–40.

Article  CAS  Google Scholar 

Hideshima T, Anderson KC. Signaling pathway mediating myeloma cell growth and survival. Cancers. 2021;13:216.

Article  CAS  PubMed  PubMed Central  Google Scholar 

John L, Krauth MT, Podar K, Raab MS. Pathway-directed therapy in multiple myeloma. Cancers. 2021;13:1668.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122:3456–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu J, Hu WX. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments. Cancer Lett. 2018;414:214–21.

Article  CAS  PubMed  Google Scholar 

Perroud C, Thurian D, Andres M, Künzi A, Wiedemann G, Zeerleder S, et al. Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma. Hematol Oncol. 2023;41:912–21.

Article  CAS  PubMed  Google Scholar 

Shaffer AL, Emre NCT, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454:226–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matthews GM, de Matos Simoes R, Dhimolea E, Sheffer M, Gandolfi S, Dashevsky O, et al. NF-κB dysregulation in multiple myeloma. Semin Cancer Biol. 2016;39:68–76.

Article  CAS  PubMed  Google Scholar 

Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, et al. Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis. 2017;6:e337.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zöllinger A, Stühmer T, Chatterjee M, Gattenlöhner S, Haralambieva E, Müller-Hermelink HK, et al. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood. 2008;112:3403–11.

Article  PubMed  Google Scholar 

Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, et al. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J. 2017;7:e535.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gagliardi PA, Puliafito A, Primo L. PDK1: at the crossroad of cancer signaling pathways. Semin Cancer Biol. 2018;48:27–35.

Article  CAS  PubMed  Google Scholar 

Zheng N, Wei J, Wu D, Xu Y, Guo J. Master kinase PDK1 in tumorigenesis. Biochim Biophys Acta Rev Cancer. 2023;1878:188971.

Article  CAS  PubMed  Google Scholar 

Cho YY. RSK2 and its binding partners in cell proliferation, transformation and cancer development. Arch Pharm Res. 2017;40:291–303.

Article  CAS  PubMed  Google Scholar 

Cho YY. Molecular targeting of ERKs/RSK2 signaling in cancers. Curr Pharm Des. 2017;23:4247–58.

Article  CAS  PubMed  Google Scholar 

Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, et al. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Mol Cancer Ther. 2012;11:2600–9.

Article  CAS  PubMed  Google Scholar 

Chinen Y, Kuroda J, Shimura Y, Nagoshi H, Kiyota M, Yamamoto-Sugitani M, et al. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma. Cancer Res. 2014;74:7418–29.

Article  CAS  PubMed  Google Scholar 

Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, et al. The rationale for the dual-targeting therapy for RSK2 and AKT in multiple myeloma. Int J Mol Sci. 2022;23:2919.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shibata T, Watari K, Kawahara A, Sudo T, Hattori S, Murakami Y, et al. Targeting phosphorylation of Y-box-binding protein YBX1 by TAS0612 and everolimus in overcoming antiestrogen resistance. Mol Cancer Ther. 2020;19:882–94.

Article  CAS  PubMed  Google Scholar 

Katsuragawa-Taminishi Y, Mizutani S, Kawaji-Kanayama Y, Onishi A, Okamoto H, Isa R, et al. Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas. Cancer Sci. 2023;114:4691–705.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ichikawa K, Ito S, Kato E, Abe N, Machida T, Iwasaki J, et al. TAS0612, a novel RSK, AKT, and S6K inhibitor, exhibits antitumor effects in preclinical tumor models. Mol Cancer Ther. 2023;23:174–86.

Article  Google Scholar 

Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Chinen Y, Tanba K, Kuwahara-Ota S, et al. Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma. Cancer Med. 2020;9:5185–99.

Article  CAS  PubMed  PubMed Central